Yong Park

Title: Yong Park: Innovator in Anti-Angiogenic Compounds

Introduction

Yong Park is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit angiogenesis. His work is crucial for advancing treatments for diseases associated with abnormal vascular growth.

Latest Patents

Yong Park holds a patent for a compound having angiogenesis inhibitory activity, which is detailed in his patent titled "Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same." This patent describes an anti-angiogenic compound, represented by Chemical Formula I, and its pharmaceutically acceptable salts. The compound effectively suppresses angiogenesis, making it applicable for the prevention and treatment of diseases caused by aberrant activity of vascular endothelial growth factor. It is recognized as a valuable anti-angiogenic agent.

Career Highlights

Yong Park is associated with Boryung Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His research and development efforts focus on creating effective treatments that can significantly improve patient outcomes.

Collaborations

Yong Park has collaborated with notable colleagues, including Ji Han Kim and Je Hak Kim. Their combined expertise contributes to the advancement of pharmaceutical innovations.

Conclusion

Yong Park's contributions to the field of anti-angiogenic compounds highlight his role as a key inventor in the pharmaceutical industry. His work not only showcases his innovative spirit but also has the potential to impact the treatment of various diseases significantly.